Christie Poole
Family · Houston, TXNPI 1093208241
Payments from drug & device makers
Across 473 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Dexcom, Inc.$1K
- Lilly USA, LLC$583
- Novo Nordisk$542
- Insulet Corporation$517
- Sanofi-aventis U.S. LLC$467
- plus $5K from 49 others
What the payments were for
- Travel & lodging$1,30413%
- Food & beverage$8,64087%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,969 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $148,116 |
| MounjaroTirzepatide | 65 | $87,518 |
| JardianceEmpagliflozin | 40 | $56,065 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 19 | $49,084 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $42,793 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 35 | $42,526 |
| TrulicityDulaglutide | 26 | $38,622 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $36,073 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $24,419 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $22,392 |
| FarxigaDapagliflozin Propanediol | 19 | $18,361 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $14,721 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,684 |
| Humalog Kwikpen U-100Insulin Lispro | 28 | $9,316 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 83 | $8,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $542 | $148,116109 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $583 | $127,739108 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $239 | $98,59175 claims |
| AmgenEvenity (2 Syringes) | $362 | $49,08419 claims |
| AstraZenecaFarxiga | $228 | $18,36119 claims |
| IBSA Pharma Inc.Tirosint | $127 | $4,48120 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $149 | $2,699138 claims |
| AbbVieSynthroid | $359 | $2,60943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.